ASPI stock — the public-equity ticker for ASP Isotopes Inc. on NASDAQ — gets priced by most retail flow as a uranium-enrichment pure-play. That framing leaves two of the three commercial verticals out of the bull case. The aerodynamic separation process at the centre of this company is feedstock-agnostic, and the same plant architecture is being scaled across three end-markets: high-assay low-enriched uranium (HALEU) for advanced nuclear reactors, medical isotopes for cancer diagnostics and radioligand therapy, and silicon-28 for next-generation semiconductors and quantum-computing substrates. Three catalyst clocks. One enrichment platform. Roughly three independent shots on goal between now and end-2027.

ASPI — the ticker for ASP Isotopes Inc. on NASDAQ — last printed $6.93 going into publication on May 27, 2026, after a year in which a sequence of contract announcements and the planned Quantum Leap Energy spinoff have transformed the equity story from a speculative pre-revenue play into a multi-vertical enrichment platform with contracted forward revenue. The market still prices the story on HALEU headlines, but the revenue base today is medical-isotope enrichment in Pretoria — and that is the misclassification the rest of this piece pulls apart.

Why ASPI stock looks different from a typical nuclear-fuel pure-play

Most ASPI stock flow tracks HALEU headlines. When the DOE announces an allocation, when TerraPower files a permit, when Cameco gives forward guidance — that’s when the position gets reordered. But the company’s revenue base today doesn’t come from uranium. It comes from molybdenum-100, under a 25-year supply agreement with BRICEM worth up to $27 million per annum, and is about to come from silicon-28 and ytterbium-176 as the Pretoria commercial production line ramps in 2026.

The misclassification matters because the catalyst clocks on the three verticals are decoupled. A delay at Pelindaba — the planned HALEU site — doesn’t push out medical-isotope shipments from Pretoria. A regulatory hiccup on Si-28 sampling for a hyperscaler doesn’t change the Pluvicto-adjacent Yb-176 demand pull from Novartis. A bear writing the Mo-100 cycle as boring doesn’t subtract from the optionality embedded in the Quantum Leap Energy spinoff. Three independent risk axes, three independent reward axes — and the market is currently pricing one of them.

The closest analogue we have written is the BITF/KEEL “miners are AI infrastructure” piece — same shape of misclassification (the market knows you for one business; you actually run three).

What ASP Isotopes actually does

The technology under the hood is the aerodynamic separation process — ASP — originally developed by Klydon Proprietary Ltd in South Africa, with roots that trace back to the country’s 1980s uranium-enrichment program. The mechanics are unusual: isotope feedstock in raw gas form is injected tangentially at high speed into a curved-wall tube. The injection creates two co-rotating vortexes around the geometrical axis. Mass-driven radial separation occurs at spin speeds of several hundred metres per second. No moving parts. No rotating centrifuges. The technical literature describes it as a “stationary-wall centrifuge.”

ASP Isotopes itself, incorporated in Delaware in September 2021 and headquartered in Dallas, acquired Klydon’s two operating pilot plants in Pretoria — one for oxygen-18 (commissioned October 2015), one for silicon-28 (commissioned July 2018) — in July 2022. The plants and the IP became the foundation of the commercial platform.

Today the operating footprint splits across four locations:

• Pretoria, South Africa — existing commercial plants for non-uranium isotopes (Mo-100, Si-28, C-14, Yb-176). Initial 2026 commercial shipments target these chemistries.
• Pelindaba, South Africa — planned HALEU enrichment plant funded via a TerraPower term loan. Different site from Pretoria, dedicated to the uranium vertical.
• Iceland — planned enrichment plant cluster capitalising on low-cost geothermal energy; medical isotopes first, silicon-28 to follow later in the decade.
• United States — Quantum Leap Energy corporate HQ in Austin, Texas, plus the Fermi America joint venture for U.S. stable-isotope and nuclear fuel production.

The HALEU vertical is run through a wholly-owned subsidiary, Quantum Leap Energy (QLE), with an additional UK entity already in early engagement with British nuclear regulators. ASP Isotopes plans to spin a portion of QLE common equity to its shareholders during 2026, retaining a 10% perpetual royalty on all QLE revenues — meaning ASPI holders get both the spinoff stake and an ongoing cash-flow claim on the HALEU business.

Vertical 1 — HALEU and the SMR supply gap

The first vertical is the loud one. HALEU — high-assay low-enriched uranium, enriched between 5% and just under 20% — is the fuel that essentially every U.S. advanced-reactor design requires. TerraPower’s Natrium. X-energy’s Xe-100. Kairos. Oklo. The full demonstration cohort. The supply gap is real and well-documented: the U.S. has no commercial-scale HALEU enrichment capability today, the existing Centrus and Orano timelines won’t cover demonstration-reactor first-fuel needs, and the geopolitical preference for non-Russian, non-Chinese sourcing has narrowed the field of acceptable suppliers further.

The Department of Energy’s HALEU Availability Program, authorised by the Energy Act of 2020 and funded with roughly $2.7 billion, has issued conditional commitments to five U.S. nuclear developers — but the bottleneck isn’t allocation, it’s production.

ASP Isotopes positions QLE as a second-source diversifier. The confirmed customer book as of late May 2026:

• TerraPower — definitive agreements signed May 2025. A term loan from TerraPower funds construction of the Pelindaba HALEU plant. A first-core supply agreement provides up to approximately $375 million of HALEU for the initial Natrium plant in Wyoming, supporting 2027/28 loading. A long-term supply agreement covers up to 150 metric tons of HALEU over a 10-year window (2028–2037), valued at up to roughly $3.75 billion. World Nuclear News covered the deal.
• Necsa (South African Nuclear Energy Corporation) — pre-implementation services contract executed February 2026 for joint HALEU R&D and commercial production.
• European nuclear technology partner — non-binding memorandum of understanding signed May 2026 for HALEU supply collaboration beginning in 2028. The partner’s name has not been publicly disclosed.

Production target at Pelindaba is 2027, subject to permits and licensing. That timing aligns with the Natrium first-fuel-core window, which is the load-bearing piece of the TerraPower agreement — slip the production date and the optionality on the long-term 150-tonne contract drifts with it. This is the same single-name catalyst-clock structure we have written about for CLSK and ONDS: the deal is signed, the revenue is contingent on execution, and the next 18 months are about whether commissioning hits its dates.

Vertical 2 — Medical isotopes (Mo-100, Yb-176, Zn-68)

The second vertical is the steady one. Three feedstocks, three end-markets, all in nuclear medicine.

Mo-100 is the stable precursor that, via neutron irradiation, produces Mo-99 and then — by radioactive decay — the imaging workhorse technetium-99m. Tc-99m runs through roughly 80% of all nuclear-medicine diagnostic scans worldwide — heart, lung, liver, bone, oncology — and the U.S. alone runs about 56,000 patient studies a day on the back of it. The Mo-99 supply chain has been chronically short for two decades, with multiple research-reactor-led shortages in the last ten years. ASP Isotopes has a 25-year Mo-100 supply agreement with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy), valued at up to $27 million per annum — a contracted revenue floor of roughly $675 million over the life of the deal. Commercial Mo-100 production is already running at the Pretoria plant.

Yb-176 is the precursor to lutetium-177 — the beta-emitting therapeutic radionuclide that powers Novartis’s Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (approved by the FDA in 2022) and its companion radioligand-therapy programs including Lutathera. Yb-176 has historically been a Russian-dominant supply chain. Non-Russian sources have become a strategic priority for Western pharma, and ASP Isotopes plus SHINE Technologies are the two most-named Western alternatives.

Zn-68 targets the gallium-68 PET imaging market. Enriched Zn-68 in a cyclotron, via the (p,n) nuclear reaction, produces Ga-68 — the workhorse PET isotope for neuroendocrine-tumour and prostate-cancer imaging, and the diagnostic half of the modern “theranostic” pairing with Lu-177 therapy. ASP markets Zn-68 as the more scalable alternative to current Ge-68/Ga-68 generator chemistry, which is liquid-target-based and expensive to scale.

Why ASP wins here: low-volume, high-margin enrichment is exactly what the aerodynamic process is suited for relative to centrifuge cascades, which need much larger throughput to be economic. Medical isotopes are a “small but sticky” revenue line — the contract durations (25 years for BRICEM) reflect that.

Vertical 3 — Silicon-28 for advanced semiconductors and quantum

The third vertical is the speculative one — and potentially the largest TAM long-term.

Natural silicon is a mix of three stable isotopes: Si-28 (about 92%), Si-29 (about 5%), Si-30 (about 3%). Removing Si-29 and Si-30 leaves an isotopically pure layer with no nuclear spin. That matters in two places:

1. Quantum computing. Spin qubits hosted in isotopically purified silicon have dramatically longer coherence times because the surrounding “solid-state vacuum” has no nuclear spins to decohere them. Published results in the academic literature show roughly 1,000× longer qubit lifetimes — milliseconds versus microseconds — relative to natural silicon. Room-temperature coherence of over 39 minutes has been documented for phosphorus-31 donors in 99.992%-enriched Si-28 (Princeton). Intel’s spin-qubit program (Tunnel Falls test chip; the Horse Ridge cryogenic control silicon), Silicon Quantum Computing (the UNSW Sydney spinout), Diraq, and academic groups at Princeton and UNSW all build directly on isotopically purified silicon. Other quantum platforms — superconducting, trapped-ion, photonic, and topological — do not depend on Si-28, but the spin-qubit-in-silicon track has become a serious branch of the modular qubit race.
2. Advanced semiconductor thermal management. Isotopically enriched silicon has roughly 10–15% higher thermal conductivity than natural silicon (~150 W/m·K versus ~130 W/m·K is the figure most often cited in the materials literature). That sounds modest, but at the smaller process nodes — where thermal density already limits achievable clock speeds — even single-digit-percent gains compound into noticeable performance headroom.

ASP Isotopes has not publicly named specific Si-28 customers in its primary filings. That visibility gap is part of what keeps the stock priced as a uranium story. CEO commentary at investor conferences suggests initial commercial Si-28 shipments in 2026, with hyperscalers and quantum R&D labs as the target buyer set. Revenue-line contribution today is small.

We covered the broader quantum-computing investment landscape in Quantum Computing Stocks 2026 — Si-28 sits underneath that entire architecture as a supply-chain dependency the market has not yet priced.

The financial picture

ASP Isotopes is pre-revenue transitioning into early-revenue. The 2026 commercial ramp is the first window in which the income statement reflects the platform thesis rather than just the platform option.

What is actually contracted and visible:

• Mo-100 → BRICEM: up to $27 million per annum, 25-year term. Active commercial production.
• HALEU first core → TerraPower: up to $375 million, deliveries targeted 2027/28.
• HALEU long-term → TerraPower: up to $3.75 billion over 10 years, 2028–2037 deliveries.
• QLE royalty: ASP Isotopes retains a 10% perpetual royalty on all QLE revenues post-spinoff.

What requires a fresh check against the latest filings (operating cash burn, runway across the 2026–2027 build window, share count and recent capital-raise dilution, insider ownership, the capex schedule for Pelindaba and the Iceland cluster) sits in the most recent 10-Q on SEC EDGAR. The combination of contracted forward revenue and pre-commercial cash burn is a familiar small-cap shape. The open question is whether the cash bridge across 2026–2027 holds — and whether the QLE spinoff itself is structured in a way that helps or hurts that bridge.

The counter-argument

Counter-arguments — what could break this thesis:

Execution risk on commercial-scale ASP. Klydon’s Pretoria plants were pilot-scale (oxygen-18 + silicon-28). Stepping up to the HALEU plant at Pelindaba — at the throughput TerraPower needs for the Natrium first core — is engineering work that has not been done yet. The proof point is the 2027 commissioning date. If it slips by 12+ months, the long-term contract starts to look optional rather than contracted.

Capital intensity. Enrichment plants take three to five years from groundbreak to first product. The TerraPower term loan offsets some capex, not all. The balance sheet has to bridge across that build window. A weak equity-issuance market in 2026 or 2027 would tighten that bridge.

Customer concentration in HALEU. TerraPower is the anchor. Necsa is the partner. The European MOU is non-binding. That is not a diversified book yet. Single-customer execution risk is meaningful.

Si-28 is mostly optionality. Until ASP names a hyperscaler or a quantum customer in a primary filing, the Si-28 thesis is structural argument rather than contracted revenue. The peer comparison here is closer to the early GLSI binary-readout setup — high optionality, low confirmation.

Permitting and geopolitics. HALEU enrichment in South Africa requires NRC-equivalent licensing, plus IAEA cooperation, plus alignment with U.S. non-proliferation policy. Non-zero delay risk.

QLE spinoff complexity. The royalty mechanics, governance arrangements, and dilution at spinoff add structural friction to the ASPI equity that most retail flow underestimates. A messy spinoff can compress the parent multiple even if the underlying business is fine.

Calendar of upcoming catalysts

The catalyst calendar that matters between now and end-2027:

2026 — second half:

• Initial commercial Si-28, C-14, and Yb-176 shipments from Pretoria (per CEO investor-conference commentary).
• QLE partial-equity spinoff to ASPI shareholders — record date and exact structure to be announced.
• Iceland plant cluster permitting milestones.
• Pelindaba HALEU plant construction progress milestones (TerraPower-funded).
• Quarterly 10-Q updates on cash position, contract bookings, and capital structure.

2027:

• Pelindaba HALEU plant commissioning — the load-bearing date for the TerraPower first-core agreement.
• First HALEU production runs (subject to permits).
• Additional customer announcements in the HALEU vertical — these matter for the diversification argument.
• Possible pharma named partnership announcements on the medical-isotope side (Lu-177 supply, Ga-68 supply).

2028 and beyond:

• TerraPower 10-year long-term supply deliveries begin.
• European partner non-binding MOU converts to firm contract (or doesn’t).
• Si-28 commercial shipments at scale (or visibility into named hyperscaler/quantum customers).

The clock that matters most is the 2027 Pelindaba commissioning date. Everything downstream — the long-term supply revenue, the diversification narrative, the bear-case-on-execution debate — is keyed to it.

Bottom line

The bottom line on this story isn’t “buy nuclear.” It’s that this is a platform-technology equity with three asymmetric verticals running on the same plant architecture. Most of the retail bull case prices the loudest of the three — HALEU — and ignores the other two, even though medical isotopes are already in commercial production and silicon-28 is the optionality leg with the largest potential TAM. Most of the retail bear case prices execution risk on a single deal (TerraPower) and ignores the Mo-100 floor that is already running.

What would change our reading: a primary-source-confirmed Si-28 hyperscaler or quantum customer; a six- or 12-month slip on the Pelindaba commissioning date; or a competitive HALEU enricher coming online faster than the consensus 2028+ timeline. Until one of those moves, the thesis stays the way the brief framed it — three independent catalyst clocks, one platform, one ticker. We are watching the Pelindaba site progress reports, the QLE spinoff record date, and any 8-K naming a Si-28 customer.